LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+8.76%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$701M
AUM Growth
+$701M
(-3.2%)
Cap. Flow
-$35.3M
Cap. Flow
% of AUM
-5.03%
Top 10 Holdings %
Top 10 Hldgs %
53.83%
Holding
68
New
17
Increased
15
Reduced
11
Closed
15
Top Buys
| 1 |
Rocket Pharmaceuticals
RCKT
|
$35.3M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$15.3M |
| 3 |
Roivant Sciences
ROIV
|
$14M |
| 4 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$13.5M |
| 5 |
IDEAYA Biosciences
IDYA
|
$13.5M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$35.9M |
| 2 |
Biogen
BIIB
|
$28.5M |
| 3 |
Immunovant
IMVT
|
$25M |
| 4 |
Neurocrine Biosciences
NBIX
|
$16.9M |
| 5 |
Arcellx
ACLX
|
$15.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Immunovant
IMVT
$2.56B
| $61.4M | 8.19% | 1,600,000 -650,000 | -29% | -$25M |
|
|
2
IDEAYA Biosciences
IDYA
$2.15B
| $60.7M | 8.1% | 2,250,000 +500,000 | +29% | +$13.5M |
|
3
Olema Pharmaceuticals
OLMA
$375M
| $46.2M | 6.17% | 3,743,875 | – | – |
|
|
4
Rocket Pharmaceuticals
RCKT
$354M
| $40.5M | 5.4% | 1,975,000 +1,725,000 | +690% | +$35.3M |
|
5
Cytokinetics
CYTK
$4.23B
| $36.8M | 4.91% | 1,250,000 -400,000 | -24% | -$11.8M |
|
6
Akero Therapeutics
AKRO
$3.74B
| $30.3M | 4.05% | 600,000 +80,000 | +15% | +$4.05M |
|
7
Apellis Pharmaceuticals
APLS
$3.48B
| $28.5M | 3.81% | 750,000 +125,000 | +20% | +$4.76M |
|
8
Structure Therapeutics
GPCR
$1.11B
| $25.2M | 3.36% | 500,000 +100,000 | +25% | +$5.04M |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $24.2M | 3.23% | 200,000 -100,000 | -33% | -$12.1M |
|
10
Immunocore
IMCR
$1.62B
| $23.4M | 3.12% | 450,000 -50,000 | -10% | -$2.6M |
|
|
ICVX
11
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $21.4M | 2.86% | 2,765,741 +600,000 | +28% | +$4.65M |
|
12
Dyne Therapeutics
DYN
$1.92B
| $19.5M | 2.61% | 2,180,000 +400,000 | +22% | +$3.58M |
|
|
KRTX
13
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $19.4M | 2.59% | 115,000 +80,000 | +229% | +$13.5M |
|
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $16.9M | 2.25% | 150,000 -150,000 | -50% | -$16.9M |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $16.1M | 2.15% | 1,050,000 -75,000 | -7% | -$1.15M |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $15.4M | 2.05% | 450,000 +175,000 | +64% | +$5.98M |
|
|
CERE
17
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $15.3M | 2.04% | +700,000 | New | +$15.3M |
|
|
18
Roivant Sciences
ROIV
$8.15B
| $14M | 1.87% | +1,200,000 | New | +$14M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $13.1M | 1.74% | +300,000 | New | +$13.1M |
|
20
Annexon
ANNX
$226M
| $12.5M | 1.67% | 5,300,000 +1,800,000 | +51% | +$4.25M |
|
21
Immatics
IMTX
$619M
| $12.2M | 1.62% | 1,050,000 +550,000 | +110% | +$6.37M |
|
22
Design Therapeutics
DSGN
$315M
| $11.9M | 1.58% | 5,032,501 +2,235,000 | +80% | +$5.27M |
|
|
ALLK
23
DELISTED
Allakos
ALLK
| $10.6M | 1.41% | 4,650,000 -600,000 | -11% | -$1.36M |
|
24
BridgeBio Pharma
BBIO
$9.89B
| $10.5M | 1.41% | 400,000 +100,000 | +33% | +$2.64M |
|
25
Rhythm Pharmaceuticals
RYTM
$6.85B
| $9.17M | 1.22% | +400,000 | New | +$9.17M |
|